Respiratory Syncytial Virus Infection
📧 Sign up to get email alerts when something new happens for Respiratory Syncytial Virus Infection.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-02-03Clinical Trial Update: Effectiveness of ABRYSVO® Maternal Respiratory Syncytial Virus (RSV) Vaccine Against RSV in Infants in Western Pennsylvania
This ClinicalTrials.gov update reports on the effectiveness of Pfizer's ABRYSVO maternal RSV vaccine in preventing RSV in infants in Western…
-
CLINICAL_TRIALS trial_result · 2026-02-03Clinical Trial Update: Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers [Phase 3]
A phase 3 trial evaluating the efficacy, immunogenicity, and safety of Sanofi Pasteur's RSV vaccine in infants and toddlers has been termina…
-
CLINICAL_TRIALS trial_result · 2026-02-03Clinical Trial Update: Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers [Phase 3]
A Phase 3 trial evaluating co-administration of an investigational live-attenuated Respiratory Syncytial Virus vaccine in infants and toddle…
-
CLINICAL_TRIALS trial_result · 2026-01-30Clinical Trial Update: A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age [Phase 3]
Phase 3 trial examining mRNA-1345 given after a licensed protein subunit RSV vaccine in adults aged 60 and older; study status is Active Not…
-
CLINICAL_TRIALS trial_result · 2026-01-26Clinical Trial Update: Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA) [Phase 1, Phase 2]
Phase 1/2 trial of a live-attenuated RSV vaccine by Sanofi Pasteur to evaluate safety, transmissibility, and genetic stability of the vaccin…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-01-26Clinical Trial Update: The Impact of Age on Adaptive Immunity in Adults Infected With Respiratory Syncytial Virus [NA]
A trial evaluating how age affects adaptive immunity in adults infected with respiratory syncytial virus. The study has completed and result…
-
CLINICAL_TRIALS trial_result · 2026-01-16Clinical Trial Update: A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age. [Phase 1]
Sanofi completed a Phase 1 clinical trial evaluating the safety and immunogenicity of vaccines targeting influenza, respiratory syncytial vi…
-
CLINICAL_TRIALS trial_result · 2026-01-08Clinical Trial Update: Covid Flu A/B and RSV 4 in 1 Diagnostic Test
Clinical trial update on a 4-in-1 diagnostic test for detecting Influenza A, Influenza B, COVID-19, and RSV, sponsored by iHealth Labs Inc.,…
-
CLINICAL_TRIALS trial_result · 2025-12-30Clinical Trial Update: A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age [Phase 3]
Phase 3 results for Moderna's RSV vaccine candidate mRNA-1345 in adults aged 50 and older have been posted after study completion.
-
CLINICAL_TRIALS trial_result · 2025-12-30Clinical Trial Update: A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV [Phase 1]
Phase 1 study of Sisunatovir in infants and children with pneumonia due to respiratory syncytial virus was terminated; results have been pos…
-
CLINICAL_TRIALS trial_result · 2025-12-26Clinical Trial Update: A Study in India on the Immune Response and Safety of a Respiratory Syncytial Virus (RSV) Older Adults (OA) Vaccine When Given to Older Adults 60 Years of Age and Above and Adults 50-59 Years of Age at Increased Risk (AIR) of Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV-LRTD) [Phase 3]
Phase 3 study assessing immune response and safety of the RSV vaccine Arexvy in adults aged 50-59 at increased risk and 60 years and older; …
-
CLINICAL_TRIALS trial_result · 2025-12-17Clinical Trial Update: Phase II Clinical Trial of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 50 Years or Above [Phase 2]
Phase II clinical trial update for a lyophilized mRNA vaccine targeting respiratory syncytial virus in adults aged 50 years or older. The st…
-
CLINICAL_TRIALS trial_result · 2025-12-17Clinical Trial Update: Phase I Clinical Trial of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 18 Years or Above [Phase 1]
This entry updates a Phase 1 clinical trial of a lyophilized mRNA vaccine for respiratory syncytial virus in adults; the study is currently …
-
CLINICAL_TRIALS trial_result · 2025-12-15Clinical Trial Update: A Study of BLB-201 RSV Vaccine in Infants and Children [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating BLB-201 RSV vaccine in infants and children is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-11-25Clinical Trial Update: A Clinical Trial of SIBP-A16 Injection in Healthy Adults [EARLY_Phase 1]
This entry reports an early-phase 1 clinical trial of SIBP-A16 Injection in healthy adults, evaluating safety for potential use against resp…
-
CLINICAL_TRIALS trial_result · 2025-11-20Clinical Trial Update: Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years [Phase 1]
Phase 1 study evaluating the safety and immune response of an investigational vaccine for Respiratory syncytial virus infection and Human me…
-
CLINICAL_TRIALS trial_result · 2025-11-10Clinical Trial Update: A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection [Phase 2, Phase 3]
Pfizer's Phase 2/3 study of sisunatovir in adults with Respiratory Syncytial Virus infection was terminated and results were posted in 2025.
-
CLINICAL_TRIALS trial_result · 2025-11-06Clinical Trial Update: A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults [Phase 3]
Phase 3 study evaluating the safety and immunogenicity of RSVpreF coadministered with the herpes zoster vaccine in adults has completed.
-
CLINICAL_TRIALS trial_result · 2025-11-05Clinical Trial Update: BEYFORTUS™ (Nirsevimab) Effectiveness Against Medically-Attended RSV Events in Infants (BEAR Study)
This clinical trial update reports on the BEAR study evaluating BEYFORTUS (nirsevimab) for preventing medically attended respiratory syncyti…
-
CLINICAL_TRIALS trial_result · 2025-10-29Clinical Trial Update: Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007) [Phase 3]
Phase 3 trial MK-1654-007 evaluating Clesrovimab in infants and children at increased risk for severe respiratory syncytial virus infection …
-
CLINICAL_TRIALS trial_result · 2025-10-27Clinical Trial Update: Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF) [Phase 4]
Phase 4 clinical trial assessing the immunogenicity of respiratory syncytial virus vaccines in residents of long-term care facilities; resul…
-
CLINICAL_TRIALS trial_result · 2025-10-07Clinical Trial Update: A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model [Phase 2]
This update reports results from a controlled Phase 2a trial evaluating EDP-323 for respiratory syncytial virus infection in a virus challen…
-
CLINICAL_TRIALS trial_result · 2025-09-25Clinical Trial Update: A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above [Phase 3]
A Phase 3 study evaluating the immune response and safety of GlaxoSmithKline's RSV vaccine in adults aged 18 to 49 at increased risk for RSV…
-
CLINICAL_TRIALS trial_result · 2025-09-25Clinical Trial Update: A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Adults. [Phase 3]
Pfizer reported results from a Phase 3 study evaluating the safety, tolerability and immunogenicity of RSVpreF delivered in multidose vials …
-
CLINICAL_TRIALS trial_result · 2025-09-19Clinical Trial Update: First Year Impact of Nirsevimab on Paediatric Respiratory Syncytial Virus Infection and Hospitalisations in the Australian Capital Territory
The study reports on the first-year impact of Nirsevimab on pediatric Respiratory Syncytial Virus infection and related hospitalisations in …